Abstract:Rosacea is a chronic skin inflammatory disease with a global prevalence ranging from 1% to 20%. It is characterized by facial erythema, telangiectasia, papules, pustules, and ocular manifestations. Its pathogenesis involves a complex interplay of genetic, environmental, immune, microbial, and neurovascular factors. Recent studies have advanced our understanding of its molecular basis, focusing on toll-like receptor (TLR) 2 pathways, LL37 expression, mammalian target of rapamycin (mTOR) activation, interleukin (IL)-17 signaling, transient receptor potential vanilloid (TRPV) functions, and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. LL37-associated signaling pathways, particularly involving TLR2 and mTORC1, are critical in the pathogenesis of rosacea. LL37 interacts with signaling molecules such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), nuclear factor kappa B (NF-κB), inflammasomes, C-X-C motif chemokine ligand 8 (CXCL8), mas-related G-protein-coupled receptor X2 (MRGPRX2)-TRPV4, and vascular endothelial growth factor (VEGF). This interaction activates macrophages, neutrophils, mast cells, and vascular endothelial cells, leading to cytokine release including tumor necrosis factor-alpha (TNF-α), IL-6, IL-1β, C motif chemokine ligand (CCL) 5, CXCL9, and CXCL10. These processes contribute to immune response modulation, inflammation, and angiogenesis in rosacea pathophysiology. The IL-17 signaling pathway also plays a crucial role in rosacea, affecting angiogenesis and the production of inflammatory cytokines. In addition, recent insights into the JAK/STAT pathways have revealed their integral role in inflammatory and angiogenic mechanisms associated with rosacea. Rosacea treatment currently focuses on symptom management, with emerging insights into these molecular pathways providing more targeted and effective therapies. Biological agents targeting specific cytokines, IL-17 inhibitors, JAK inhibitors, and VEGF antagonists are promising for future rosacea therapy, aiming for enhanced efficacy and fewer side effects. This review provides a comprehensive overview of the current knowledge regarding signaling pathways in rosacea and potential targeted therapeutic strategies.

ADAMDEC1 promotes skin inflammation in rosacea via modulating the polarization of M1 macrophages

LncRNA NEAT1 targets miR-125/ADAM9 mediated NF-κB pathway in inflammatory response of rosacea

GBP5 Exacerbates Rosacea‐like Skin Inflammation by Skewing Macrophage Polarization Towards M1 Phenotype Through the NF‐κB Signalling Pathway

A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea

OPN Promotes Pro-Inflammatory Cytokine Expression Via ERK/JNK Pathway and M1 Macrophage Polarization in Rosacea

Aberrant amino acid metabolism promotes neurovascular reactivity in rosacea

ROS inhibition increases KDM6A-mediated NOX2 transcription and promotes macrophages oxidative stress and M1 polarization

TLR7 Promotes Skin Inflammation Via Activating NFκB-mTORC1 Axis in Rosacea.

Single-cell transcriptomics reveals aberrant skin-resident cell populations and identifies fibroblasts as a determinant in rosacea

N2-polarized Neutrophils Reduce Inflammation in Rosacea by Regulating Vascular Factors and Proliferation of CD4+ T Cells.

Targeting Aquaporin-3 Attenuates Skin Inflammation in Rosacea.

Signaling pathways and targeted therapy for rosacea

Keratinocyte-Immune Cell Crosstalk in a STAT1-Mediated Pathway: Novel Insights Into Rosacea Pathogenesis

Increased Serum Levels of CCL3, CXCL8, CXCL9, and CXCL10 in Rosacea Patients and Their Correlation with Disease Severity.

Aquaporin-3 Upregulation Promotes Rosacea-Like Inflammation by Inducing NF-kB Activation in Keratinocytes and Th17 Cell Differentiation

Integrated Omics Reveal the Molecular Characterization and Pathogenic Mechanism of Rosacea.

Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation.

Regulatory Factor X1 Induces Macrophage M1 Polarization by Promoting DNA Demethylation in Autoimmune Inflammation.

Artemisinin, a Potential Option to Inhibit Inflammation and Angiogenesis in Rosacea.

Advances in the study of macrophage polarization in inflammatory immune skin diseases

A novel role for the ROS-ATM-Chk2 axis mediated metabolic and cell cycle reprogramming in the M1 macrophage polarization